Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)

INTRODUCTION: Drug development and clinical decision making for patients with metastatic prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing changes in bony disease burden that are associated with overall survival (OS). Bone scan index (BSI), a quantitative imaging...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Urol Oncol
Autori principali: Armstrong, Andrew J., Kaboteh, Reza, Carducci, Michael A., Damber, Jan-Erik, Stadler, Walter M., Hansen, Mats, Edenbrandt, Lars, Forsberg, Göran, Nordle, Örjan, Pili, Roberto, Morris, Michael J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6341998/
https://ncbi.nlm.nih.gov/pubmed/25240761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2014.08.006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi